

Publications Nutrition & Cancer

Last Update: April 2017



- 1 Effect of sugar on cancer development
- 2 Ketogenic Nutrition / Metabolic Therapy

- 3 Nutrition and sugar in cancer care
- 4 Special food ingredients

1 Effect of sugar on cancer development

Bruijn, K. M. de et al. (2013): Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. *Br J Surg* 100 (11): 1421–1429.

Eslamian, G. et al. (2013): Higher glycemic index and glycemic load diet is associated with increased risk of esophageal squamous cell carcinoma: a case-control study. *Nutr Res* 33 (9): 719–725.

Gnagnarella, P. et al. (2008): Glycemic index, glycemic load, and cancer risk: a meta-analysis. *Am J Clin Nutr* 87 (6): 1793–1801.

Goto, A. et al. (2016): High hemoglobin A1c levels within the non-diabetic range are associated with the risk of all cancers. *Int J Cancer* 138 (7): 1741–1753.

Hu, J. et al. (2013): Glycemic index, glycemic load and cancer risk. *Ann Oncol* 24 (1): 245–251.

Hua, F.; Yu, J. J.; Hu, Z. W. (2016): Diabetes and cancer, common threads and missing links. *Cancer Lett* 374 (1): 54–61.

Huang, Y. et al. (2014): Prediabetes and the risk of cancer: a meta-analysis. *Diabetologia* 57 (11): 2261–2269.

Romieu, I. et al. (2012): Dietary glycemic index and glycemic load and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Am J Clin Nutr* 96 (2): 345–355.

Schmidt, J. A. et al. (2014): Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev* 23 (6): 976–985.

Turati, F. et al. (2015): High glycemic index and glycemic load are associated with moderately increased cancer risk. *Mol Nutr Food Res* 59 (7): 1384–1394.

2 Ketogenic Nutrition / Metabolic Therapy

Abdelwahab, Mohammed G. et al. (2012): The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. *PLoS One* 7 (5)e36197.

Allen, B. G. et al. (2014): Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism. *Redox Biol* 2: 963–970.

Allen, Bryan G. et al. (2013): Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. *Clin Cancer Res* 19 (14): 3905–3913.

Brand, A. et al. (2016): LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. *Cell Metab* 24(5):657-671.

Branca, J. J.; Pacini, S.; Ruggiero, M. (2015): Effects of Pre-surgical Vitamin D Supplementation and Ketogenic Diet in a Patient with Recurrent Breast Cancer. *Anticancer Res* 35 (10): 5525–5532.

Branco, A. F. et al. (2016): Ketogenic diets: from cancer to mitochondrial diseases and beyond. *Eur J Clin Invest* 46 (3): 285–298.

Brandhorst, S. et al. (2017): Protective effects of short-term dietary restriction in surgical stress and chemotherapy. *Ageing Res Rev*.

Breitkreutz, R. et al. (2005): Effects of a high-fat diet on body composition in cancer patients receiving chemotherapy: a randomized controlled study. *Wien Klin Wochenschr* 117 (19-20): 685–692.

Champ, C. E. et al. (2013): Nutrient restriction and radiation therapy for cancer treatment: when less is more. *Oncologist* 18 (1): 97–103.

- Champ, C. E. et al. (2014): Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. *J Neurooncol* 117 (1): 125–131.
- Chang, H. T.; Olson, L. K.; Schwartz, K. A. (2013): Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. *Nutr Metab (Lond)* 10 (1): 47.
- El, Mjiyad N. et al. (2011): Sugar-free approaches to cancer cell killing. *Oncogene* 30 (3): 253–264.
- Emond, J. A. et al. (2014): Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGF1 receptor. *Cancer Epidemiol Biomarkers Prev* 23 (7): 1273–1279.
- Fine, E. J. et al. (2009): Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. *Cancer Cell Int* 9: 14.
- Fine, E. J. et al. (2012): Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. *Nutrition* 28 (10): 1028–1035.
- Fogg, V. C.; Lanning, N. J.; Mackeigan, J. P. (2011): Mitochondria in cancer: at the crossroads of life and death. *Chin J Cancer* 30 (8): 526–539.
- Freedland, S. J. et al. (2008): Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. *Prostate* 68 (1): 11–19.
- Gatenby, R. A.; Gillies, R. J. (2004): Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* 4 (11): 891–899.
- Groot, S. de et al. (2015): The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. *BMC Cancer* 15: 652.
- Ho, V. W. et al. (2011): A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. *Cancer Res* 71 (13): 4484–4493.
- Hsu, P. P.; Sabatini, D. M. (2008): Cancer cell metabolism: Warburg and beyond. *Cell* 134 (5): 703–707.
- Husain, Z. et al. (2013): Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. *J Immunol* 191 (3): 1486–1495.
- Jansen, N.; Walach, H. (2016): The development of tumours under a ketogenic diet in association with the novel tumour marker TKTL1: A case series in general practice. *Oncol Lett* 11 (1): 584–592.
- Kankova, K.; Hrstka, R. (2012): Cancer as a metabolic disease and diabetes as a cancer risk? *Klin Onkol* 25 Suppl 22S26-31.
- Klement, R. J. (2014): Restricting carbohydrates to fight head and neck cancer-is this realistic? *Cancer Biol Med* 11 (3): 145–161.
- Klement, R. J.; Champ, C. E. (2014): Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. *Cancer Metastasis Rev* 33 (1): 217–229.
- Klement, R. J.; Kammerer, U. (2011): Is there a role for carbohydrate restriction in the treatment and prevention of cancer? *Nutr Metab (Lond)* 8: 75.
- Klement, R. J.; Sweeney, R. A. (2016): Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. *BMC Res Notes* 9: 143.
- Lee, C. et al. (2012): Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. *Sci Transl Med* 4 (124)124ra27.
- Lee, C.; Longo, V. D. (2011): Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. *Oncogene* 30 (30): 3305–3316.

- Longo, V. D.; Fontana, L. (2010): Calorie restriction and cancer prevention: metabolic and molecular mechanisms. *Trends Pharmacol Sci* 31 (2): 89–98.
- Lv, M. et al. (2014): Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. *PLoS One* 9 (12): e115147.
- Marinac, Catherine R. et al. (2016): Prolonged Nightly Fasting and Breast Cancer Prognosis. *JAMA Oncol* 2 (8): 1049–1055.
- Maurer, G. D. et al. (2011): Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. *BMC Cancer* 11: 315.
- Meijer, T. W. et al. (2012): Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. *Clin Cancer Res* 18 (20): 5585–5594.
- Oliveira, Camila L.P. et al. (2017): A Nutritional Perspective of Ketogenic Diet in Cancer. A Narrative Review. *Journal of the Academy of Nutrition and Dietetics*.
- Raffaghello, L. et al. (2010): Fasting and differential chemotherapy protection in patients. *Cell Cycle* 9 (22): 4474–4476.
- Rieger, J. et al. (2014): ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. *Int J Oncol* 44 (6): 1843–1852.
- Safdie, F. et al. (2012): Fasting enhances the response of glioma to chemo- and radiotherapy. *PLoS One* 7 (9): e44603.
- Schmidt, M. et al. (2011): Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. *Nutr Metab (Lond)* 8 (1): 54.
- Schroeder, U. et al. (2013): Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer. *Nutr Cancer* 65 (6): 843–849.
- Schwartz, K. et al. (2015): Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. *Cancer Metab* 3: 3.
- Seyfried, T. N. et al. (2014): Cancer as a metabolic disease: implications for novel therapeutics. *Carcinogenesis* 35 (3): 515–527.
- Shukla, S. K. et al. (2014): Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. *Cancer Metab* 2: 18.
- Smyl, C. (2016): Ketogenic Diet and Cancer—a Perspective. *Recent Results Cancer Res* 207: 233–240.
- Tan-Shalaby, J. (2017): Ketogenic Diets and Cancer. *Emerging Evidence. Fed Pract* 34 (supp 1): 375–425.
- Vergati, M. et al. (2017): Ketogenic diet and other dietary intervention strategies in the treatment of cancer. *Curr Med Chem*.
- Woolf, E. C. et al. (2015): The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model. *PLoS One* 10 (6): e0130357.
- Woolf, E. C.; Scheck, A. C. (2015): The ketogenic diet for the treatment of malignant glioma. *J Lipid Res* 56 (1): 5–10.
- Woolf, E. C.; Syed, N.; Scheck, A. C. (2016): Tumor Metabolism, the Ketogenic Diet and β -Hydroxybutyrate. *Novel Approaches to Adjuvant Brain Tumor Therapy. Front. Mol. Neurosci.* 9: e36197.
- Wright, C.; Simone, N. L. (2016): Obesity and tumor growth: inflammation, immunity, and the role of a ketogenic diet. *Curr Opin Clin Nutr Metab Care* 19 (4): 294–299.
- Zuccoli, G. et al. (2010): Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. *Nutr Metab (Lond)* 7: 33.

3 Nutrition and sugar in cancer care

Aune, D. et al. (2012): Dietary fructose, carbohydrates, glycemic indices and pancreatic cancer risk: a systematic review and meta-analysis of cohort studies. *Ann Oncol* 23 (10): 2536–2546.

Braakhuis, A. J.; Campion, P.; Bishop, K. S. (2016): Reducing Breast Cancer Recurrence: The Role of Dietary Polyphenolics. *Nutrients* 8 (9).

Champ, C. E. et al. (2012): Weight gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data? *Int J Breast Cancer* 2012: 506868.

Emond, J. A. et al. (2014): Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGF1 receptor. *Cancer Epidemiol Biomarkers Prev* 23 (7): 1273–1279.

Meyerhardt, J. A. et al. (2012): Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. *J Natl Cancer Inst* 104 (22): 1702–1711.

Minicozzi, P. et al. (2013): High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease. *Eur J Cancer* 49 (18): 3881–3888.

4 Special food ingredients

Broccoli and sulforaphane

Bauman, J. E. et al. (2016): Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. *Cancer Prev Res (Phila)* 9 (7): 547–557.

Bijangi-Vishehsaraei, K. et al. (2017): Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. *J Neurosurg*: 1–12.

Ganai, S. A. (2016): Histone deacetylase inhibitor sulforaphane: The phytochemical with vibrant activity against prostate cancer. *Biomed Pharmacother* 81: 250–257.

Jiang, L. L. et al. (2016): Sulforaphane suppresses in vitro and in vivo lung tumorigenesis through downregulation of HDAC activity. *Biomed Pharmacother* 78: 74–80.

Kallifatidis, G. et al. (2009): Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. *Gut* 58 (7): 949–963.

Kim, D. H. et al. (2015): Sulforaphane inhibits hypoxia-induced HIF-1alpha and VEGF expression and migration of human colon cancer cells. *Int J Oncol* 47 (6): 2226–2232.

Liu, K. C. et al. (2016): Sulforaphane Induces Cell Death through G2/M Phase Arrest and Triggers Apoptosis in HCT 116 Human Colon Cancer Cells. *Am J Chin Med*: 1289–1310.

Martin, S. L.; Kala, R.; Tollefsbol, T. O. (2017): Mechanisms for inhibition of colon cancer cells by sulforaphane through epigenetic modulation of microRNA-21 and human telomerase reverse transcriptase (hTERT) down-regulation. *Curr Cancer Drug Targets*.

Sarkar, R. et al. (2012): Sulphoraphane, a naturally occurring isothiocyanate induces apoptosis in breast cancer cells by targeting heat shock proteins. *Biochem Biophys Res Commun* 427 (1): 80–85.

Curcuma and curcumin

Allegra, A. et al. (2017): Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies. *Cancer Invest* 35 (1): 1–22.

Cruz-Corres et al. (2006): Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. In: *Clin Gastroenterol Hepatol* 4 (8), 1035–1038.

Deng, Y. I.; Verron, E.; Rohanizadeh, R. (2016): Molecular Mechanisms of Anti-metastatic Activity of Curcumin. *Anticancer Res* 36 (11): 5639–5647.

Naik, S.; Thakare, V.; Patil S (2011): Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: evidence of its antioxidant property. *Exp Toxicol Pathol* 63 (5): 419–431.

Killian, P. H. et al. (2012): Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. *Carcinogenesis* 33 (12): 2507–2519.

Mahlknecht, U. (2013): Den Krebs im Visier. *Aktuel Ernährungsmed* 38 (S 01)S37–S41.

Murakami, A. et al. (2013): Curcumin combined with turmerones, essential oil components of turmeric, abolishes inflammation-associated mouse colon carcinogenesis. *Biofactors* 39 (2): 221–232.

Schaffer, M.; Schaffer, P. M.; Bar-Sela, G. (2015): An update on Curcuma as a functional food in the control of cancer and inflammation. *Curr Opin Clin Nutr Metab Care* 18 (6): 605–611.

Toden, S. et al. (2015): Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer. *Cancer Prev Res (Phila)* 8 (5): 431–443.

Galactose

Isenberg, J. et al. (1997): Liver lectin blocking with D-galactose to prevent hepatic metastases in colorectal carcinoma patients. *Anticancer Res* 17 (5B): 3767–3772.

Kosik, J. et al. (1997): Prevention of hepatic metastases by liver lectin blocking with D-galactose in stomach cancer patients. A prospectively randomized clinical trial. *Anticancer Res* 17 (2B): 1411–1415.

Li, N. et al. (2011): D-galactose induces necroptotic cell death in neuroblastoma cell lines. *J Cell Biochem* 112 (12): 3834–3844.

Warczynski, P. et al. (1997): Prevention of hepatic metastases by liver lectin blocking with D-galactose in colon cancer patients. A prospectively randomized clinical trial. *Anticancer Res* 17 (2B): 1223–1226.

Green tea and EGCG

Am Dostal et al. (2015): The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. *Food Chem Toxicol* 83: 26–35.

Fujiki, H. et al. (2015): Primary cancer prevention by green tea, and tertiary cancer prevention by the combination of green tea catechins and anticancer compounds. *J Cancer Prev* 20 (1): 1–4.

Hayakawa, S. et al. (2016): Anti-Cancer Effects of Green Tea by Either Anti- or Pro- Oxidative Mechanisms. *Asian Pac J Cancer Prev* 17 (4): 1649–1654.

Hu, F. et al. (2015): EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells. *J Pharmacol Sci* 128 (1): 27–34.

Huang, Y. et al. (2015): Green tea polyphenol epigallocatechin-O-gallate induces cell death by acid sphingomyelinase activation in chronic myeloid leukemia cells. *Oncol Rep* 34 (3): 1162–1168.

Liu, J et al. (2016): Association of green tea consumption with mortality from all-cause, cardiovascular disease and cancer in a Chinese cohort of 165,000 adult men. *Eur J Epidemiol.* 2016 Sep;31(9):853-65. doi: 10.1007/s10654-016-0173-3
Titel anhand dieser DOI in Citavi-Projekt übernehmen. Epub 2016 Jul 2.

Mayr, C. et al. (2015): The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential syner-

gism with cisplatin in biliary tract cancer cells. *BMC Complement Altern Med* 15: 194.

Mereles, D.; Hunstein, W. (2011): Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? *Int J Mol Sci* 12 (9): 5592–5603.

Sanchez-Tena, S. et al. (2013): Epicatechin gallate impairs colon cancer cell metabolic productivity. *J Agric Food Chem* 61 (18): 4310–4317.

Shay, J. et al. (2015): Molecular Mechanisms and Therapeutic Effects of (-)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, and Neurodegeneration. *Oxid Med Cell Longev* 2015: 181260.

Polyphenols

Abdal, Dayem A. et al. (2016): The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms. *Nutrients* 8 (9).

Braakhuis, A. J.; Campion, P.; Bishop, K. S. (2016): Reducing Breast Cancer Recurrence: The Role of Dietary Polyphenolics. *Nutrients* 8 (9).

Jung, K. H. et al. (2013): Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1 α activation. *J Nucl Med* 54 (12): 2161–2167.

Niedzwiecki, A. et al. (2016): Anticancer Efficacy of Polyphenols and Their Combinations. *Nutrients* 8 (9).

Shen, M.; Chan, T. H.; Dou, Q. P. (2012): Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization. *Anticancer Agents Med Chem* 12 (8): 891–901.

Zhou, W. et al. (2010): Dietary polyphenol quercetin targets pancreatic cancer stem cells. *Int J Oncol* 37 (3): 551–561.

Zhou, Y. et al. (2016): Natural Polyphenols for Prevention and Treatment of Cancer. *Nutrients* 8 (8).

Omega-3 fatty acids

Lorgeril, M. de; Salen, P. (2014): Helping women to good health: breast cancer, omega-3/omega-6 lipids, and related lifestyle factors. *BMC Med* 12: 54.

Manzi, L. et al. (2015): Effect of Dietary omega-3 Polyunsaturated Fatty Acid DHA on Glycolytic Enzymes and Warburg Phenotypes in Cancer. *Biomed Res Int* 2015: 137097.

Merendino, N. et al. (2013): Dietary omega -3 polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer. *Biomed Res Int* 2013: 310186.

Mouradian, M. et al. (2015): Docosahexaenoic acid attenuates breast cancer cell metabolism and the Warburg phenotype by targeting bioenergetic function. *Mol Carcinog* 54 (9): 810–820.

Sun, H. et al. (2013): Anti-cancer activity of DHA on gastric cancer—an in vitro and in vivo study. *Tumour Biol* 34 (6): 3791–3800.

Yum, H. W.; Na, H. K.; Surh, Y. J. (2016): Anti-inflammatory effects of docosahexaenoic acid: Implications for its cancer chemopreventive potential. *Semin Cancer Biol*.

Salvestrols

Schaefer, B. A. et al. (2012): Cancer and Related Case Studies Involving Salvestrol and CYP1B1. *JOM* 27 (3): 131–138.

Schaefer, B. A. et al. (2007): Nutrition and Cancer: Salvestrol Case Studies. *JOM* 22 (2): 177–182.

Schaefer, B. A. et al. (2010): Nutrition and Cancer: Further Case Studies Involving Salvestrol. *JOM* 25 (1): 17–23.

Tan, H. L. et al. (2007): Salvestrols: A New Perspective in Nutritional Research. JOM 22 (1): 39–47.

Ware, William R. (2009): Nutrition and the prevention and treatment of cancer: association of cytochrome P450 CYP1B1 with the role of fruit and fruit extracts. Integr Cancer Ther 8 (1): 22–28.

Tocomin, vitamin E and tocotrienols

Eitsuka, T. et al. (2016): Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review. Int J Mol Sci 17 (10).

Husain, K. et al. (2011): Vitamin E delta-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kappaB activation in pancreatic cancer. Mol Cancer Ther 10 (12): 2363–2372.

Jiang, Q. et al. (2012): Gamma-tocotrienol induces apoptosis and autophagy in prostate cancer cells by increasing intracellular dihydrosphingosine and dihydroceramide. Int J Cancer 130 (3): 685–693.

Luk, S. U. et al. (2011): Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int J Cancer 128 (9): 2182–2191.

Shibata, A. et al. (2008): Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma cells by suppressing hypoxia-inducible factor-1alpha. J Nutr 138 (11): 2136–2142.

Sylvester, P. W. et al. (2014): Potential role of tocotrienols in the treatment and prevention of breast cancer. Biofactors 40 (1): 49–58.

Sylvester, P. W. et al. (2011): Tocotrienol combination therapy results in synergistic anticancer response. Front Biosci (Landmark Ed) 16: 3183–3195.

Szabolcs, P. et al. (2016): A Systematic Review of Global Alpha-Tocopherol Status as Assessed by Nutritional Intake Levels and Blood Serum Concentrations. Int J Vitam Nutr Res: 1–21.

Yap, W. N. et al. (2010): In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer. Pharmacology 85 (4): 248–258.

Vitamin D3 and vitamin K2

McDonnell, S. L. et al. (2016): Serum 25-Hydroxyvitamin D Concentrations ≥ 40 ng/ml Are Associated with 65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study. PLoS One 11 (4): e0152441.

Reichrath, J.; Reichrath, S. (2013): Die Haut als endokrines Organ. Vitamin D, Sonnenstrahlung und Krebsprävention. Zs.f.Orthomol.Med. 11 (02): 10–12.

Sada, E. et al. (2010): Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages. Eur J Haematol 85 (6): 538–548.

Spitz, J. (2014): Zur Bedeutung des Sonnenhormons Vitamin D in der Onkologie – ein Update. DZO 46 (03): 96–102.